Track topics on Twitter Track topics that are important to you
Controlled release is an essential requirement for delivery of hydrogen sulfide (HS) because of its reactive nature, short half-life in biological fluids, and toxicity at high concentrations. In this context, HS delivery via hydrogels may be beneficial as they can deliver HS locally at the site of interest. Herein, we employed hydrogels based on aromatic peptide amphiphiles (APAs) with tunable mechanical properties to modulate the rates of HS release. The APAs contained an aromatic -aroylthiooxime (SATO) HS donor attached with a linker to a short IAVEEE hexapeptide. Linker units included carbonyl, substituted -methylenes, alkenyl, and alkyl segments with the goal of evaluating the role of linker structure on self-assembly, capacity for hydrogelation, and HS release rate. We studied each peptide by transmission electron microscopy, circular dichroism spectroscopy, and rheology, and we measured HS release rates from each gel, triggering SATO decomposition and release of HS by addition of cysteine (Cys). Using an HS-selective electrode probe as well as a turn-on fluorescent HS probe in the presence of H9C2 cardiomyocytes, we found that the rate of HS release from the hydrogels depended on the rate of Cys penetration into the nanofiber core with stiffer gels showing longer overall release.
This article was published in the following journal.
Drug loading hydrogels are promising candidates in bioengineering research filed, nevertheless, hydrophobic drug loading into hydrophilic carrier system remains unsolved and is full of challenge. In t...
Subcellular delivery of nanomedicines has emerged as a promising approach to enhance the therapeutic efficacy of anticancer drugs. Nuclear accumulation of anticancer drugs are essential for its therap...
Mixed thermoreversible gels were successfully fabricated by the addition of a thermosensitive polymer, poly(N-isopropylacrylamide) (PNIPAM), to fibrillar nanostructures self-assembled from a short pep...
Injectable hydrogels from biocompatible materials are in demand for tissue engineering and drug delivery systems. Here, we produce hydrogels from mere cellulose nanocrystals (CNCs) by salt-induced cha...
Photo-responsive hydrogels from polysaccharides and Fe(III) were used as a new system to capture and release PO from waste solutions. Uptake of 0.6-1.5 mg phosphate per gram of hydrogels was determine...
The main aim of the study is to elucidate the influence of fibre-based hydrogels differing in their mechanical properties (characterized both instrumentally and sensorially) in terms of lo...
This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin releas...
This research may explain whether a shortage of three special compounds called aromatic amino acids is responsible for the severe illness and high death rate of children with the kwashiork...
Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, i...
This randomized, double blind, parallel group study, compared the efficacy of spray containing aromatic essential oils of some herbal plants, against placebo in the treatment of patients w...
Proteins that are involved in the peptide chain termination reaction (PEPTIDE CHAIN TERMINATION, TRANSLATIONAL) on RIBOSOMES. They include codon-specific class-I release factors, which recognize stop signals (TERMINATOR CODON) in the MESSENGER RNA; and codon-nonspecific class-II release factors.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
A form of antibodies (scFv) consisting of the variable regions of only the heavy and light chains, connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21)
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...